European CHMP recommends approval of new route of administration for existing formulation of peginterferon beta-1a (Plegridy)

The CHMP has recommended that the 125mcg in 0.5mL formulation, already authorised for subcutaneous use, be additionally approved for intramuscular use in the treatment of relapsing remitting multiple sclerosis.

Source:

European Medicines Agency